Enzymatic assay studies have demonstrated ceritinib to be 20 times more potent against ALK than crizotinib and preclinical studies in NSCLC have demonstrated antitumor activity against both crizotinib-sensitive and crizotinib-resistant NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.